Clinical Trial Update: Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers [Phase 3]

View source ↗

Summary

Phase 3 trial update on the efficacy and safety of ibrutinib in patients with chronic lymphocytic leukemia and indolent B-cell lymphomas who are chronic hepatit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Indolent B-cell Lymphoma
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: The University of Hong Kong | Conditions: Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas | Phase 3 | Status: UNKNOWN